65 related articles for article (PubMed ID: 38555398)
21. The complex role of tumor-infiltrating macrophages.
Christofides A; Strauss L; Yeo A; Cao C; Charest A; Boussiotis VA
Nat Immunol; 2022 Aug; 23(8):1148-1156. PubMed ID: 35879449
[TBL] [Abstract][Full Text] [Related]
22. Quantitative proteomics identifies the core proteome of exosomes with syntenin-1 as the highest abundant protein and a putative universal biomarker.
Kugeratski FG; Hodge K; Lilla S; McAndrews KM; Zhou X; Hwang RF; Zanivan S; Kalluri R
Nat Cell Biol; 2021 Jun; 23(6):631-641. PubMed ID: 34108659
[TBL] [Abstract][Full Text] [Related]
23. Cancer-Associated Fibroblasts and Tumor-Associated Macrophages in Cancer and Cancer Immunotherapy.
Raskov H; Orhan A; Gaggar S; Gögenur I
Front Oncol; 2021; 11():668731. PubMed ID: 34094963
[TBL] [Abstract][Full Text] [Related]
24. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.
Sung H; Ferlay J; Siegel RL; Laversanne M; Soerjomataram I; Jemal A; Bray F
CA Cancer J Clin; 2021 May; 71(3):209-249. PubMed ID: 33538338
[TBL] [Abstract][Full Text] [Related]
25. TREM2 Modulation Remodels the Tumor Myeloid Landscape Enhancing Anti-PD-1 Immunotherapy.
Molgora M; Esaulova E; Vermi W; Hou J; Chen Y; Luo J; Brioschi S; Bugatti M; Omodei AS; Ricci B; Fronick C; Panda SK; Takeuchi Y; Gubin MM; Faccio R; Cella M; Gilfillan S; Unanue ER; Artyomov MN; Schreiber RD; Colonna M
Cell; 2020 Aug; 182(4):886-900.e17. PubMed ID: 32783918
[TBL] [Abstract][Full Text] [Related]
26. A decade of immune-checkpoint inhibitors in cancer therapy.
Robert C
Nat Commun; 2020 Jul; 11(1):3801. PubMed ID: 32732879
[TBL] [Abstract][Full Text] [Related]
27. Syntenin-1 promotes colorectal cancer stem cell expansion and chemoresistance by regulating prostaglandin E2 receptor.
Iwamoto K; Takahashi H; Okuzaki D; Osawa H; Ogino T; Miyoshi N; Uemura M; Matsuda C; Yamamoto H; Mizushima T; Mori M; Doki Y; Eguchi H
Br J Cancer; 2020 Sep; 123(6):955-964. PubMed ID: 32595209
[TBL] [Abstract][Full Text] [Related]
28. MDA-9/Syntenin/SDCBP: new insights into a unique multifunctional scaffold protein.
Pradhan AK; Maji S; Das SK; Emdad L; Sarkar D; Fisher PB
Cancer Metastasis Rev; 2020 Sep; 39(3):769-781. PubMed ID: 32410111
[TBL] [Abstract][Full Text] [Related]
29. Effect of Combined Immune Checkpoint Inhibition vs Best Supportive Care Alone in Patients With Advanced Colorectal Cancer: The Canadian Cancer Trials Group CO.26 Study.
Chen EX; Jonker DJ; Loree JM; Kennecke HF; Berry SR; Couture F; Ahmad CE; Goffin JR; Kavan P; Harb M; Colwell B; Samimi S; Samson B; Abbas T; Aucoin N; Aubin F; Koski SL; Wei AC; Magoski NM; Tu D; O'Callaghan CJ
JAMA Oncol; 2020 Jun; 6(6):831-838. PubMed ID: 32379280
[TBL] [Abstract][Full Text] [Related]
30. MDA-9/Syntenin (SDCBP) Is a Critical Regulator of Chemoresistance, Survival and Stemness in Prostate Cancer Stem Cells.
Talukdar S; Das SK; Pradhan AK; Emdad L; Windle JJ; Sarkar D; Fisher PB
Cancers (Basel); 2019 Dec; 12(1):. PubMed ID: 31878027
[TBL] [Abstract][Full Text] [Related]
31. Inflammation induced by incomplete radiofrequency ablation accelerates tumor progression and hinders PD-1 immunotherapy.
Shi L; Wang J; Ding N; Zhang Y; Zhu Y; Dong S; Wang X; Peng C; Zhou C; Zhou L; Li X; Shi H; Wu W; Long X; Wu C; Liao W
Nat Commun; 2019 Nov; 10(1):5421. PubMed ID: 31780645
[TBL] [Abstract][Full Text] [Related]
32. MDM2 inhibitor APG-115 synergizes with PD-1 blockade through enhancing antitumor immunity in the tumor microenvironment.
Fang DD; Tang Q; Kong Y; Wang Q; Gu J; Fang X; Zou P; Rong T; Wang J; Yang D; Zhai Y
J Immunother Cancer; 2019 Nov; 7(1):327. PubMed ID: 31779710
[TBL] [Abstract][Full Text] [Related]
33. Immunotherapy in colorectal cancer: rationale, challenges and potential.
Ganesh K; Stadler ZK; Cercek A; Mendelsohn RB; Shia J; Segal NH; Diaz LA
Nat Rev Gastroenterol Hepatol; 2019 Jun; 16(6):361-375. PubMed ID: 30886395
[TBL] [Abstract][Full Text] [Related]
34. Integrin CD11b activation drives anti-tumor innate immunity.
Schmid MC; Khan SQ; Kaneda MM; Pathria P; Shepard R; Louis TL; Anand S; Woo G; Leem C; Faridi MH; Geraghty T; Rajagopalan A; Gupta S; Ahmed M; Vazquez-Padron RI; Cheresh DA; Gupta V; Varner JA
Nat Commun; 2018 Dec; 9(1):5379. PubMed ID: 30568188
[TBL] [Abstract][Full Text] [Related]
35. Syntenin1/MDA-9 (SDCBP) induces immune evasion in triple-negative breast cancer by upregulating PD-L1.
Liu J; Yang Y; Wang H; Wang B; Zhao K; Jiang W; Bai W; Liu J; Yin J
Breast Cancer Res Treat; 2018 Sep; 171(2):345-357. PubMed ID: 29845474
[TBL] [Abstract][Full Text] [Related]
36. The MDA-9/Syntenin/IGF1R/STAT3 Axis Directs Prostate Cancer Invasion.
Das SK; Pradhan AK; Bhoopathi P; Talukdar S; Shen XN; Sarkar D; Emdad L; Fisher PB
Cancer Res; 2018 Jun; 78(11):2852-2863. PubMed ID: 29572229
[TBL] [Abstract][Full Text] [Related]
37. M2-polarized and tumor-associated macrophages alter NK cell phenotype and function in a contact-dependent manner.
Krneta T; Gillgrass A; Poznanski S; Chew M; Lee AJ; Kolb M; Ashkar AA
J Leukoc Biol; 2017 Jan; 101(1):285-295. PubMed ID: 27493241
[TBL] [Abstract][Full Text] [Related]
38. Anticancer activity of pyrithione zinc in oral cancer cells identified in small molecule screens and xenograft model: Implications for oral cancer therapy.
Srivastava G; Matta A; Fu G; Somasundaram RT; Datti A; Walfish PG; Ralhan R
Mol Oncol; 2015 Oct; 9(8):1720-35. PubMed ID: 26115765
[TBL] [Abstract][Full Text] [Related]
39. Increased production of intestinal immunoglobulins in Syntenin-1-deficient mice.
Tamura K; Ikutani M; Yoshida T; Tanaka-Hayashi A; Yanagibashi T; Inoue R; Nagai Y; Adachi Y; Miyawaki T; Takatsu K; Mori H
Immunobiology; 2015 May; 220(5):597-604. PubMed ID: 25543283
[TBL] [Abstract][Full Text] [Related]
40. Syntenin is expressed in human follicular dendritic cells and involved in the activation of focal adhesion kinase.
Cho W; Kim H; Lee JH; Hong SH; Choe J
Immune Netw; 2013 Oct; 13(5):199-204. PubMed ID: 24198745
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
